Skip to main content

Advertisement

SpringerLink
Log in

When to treat patients with chronic hepatitis C

  • Invited Commentary
  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. National Institutes of Health Consensus Development Conference statement: Management of hepatitis C: 2002. June 10–12, 2002. Hepatology 2002, 36:S3–S20.

  2. Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666–1672.

    Article  PubMed  CAS  Google Scholar 

  3. Manns MP, McHutchison JG, Gordon SC, et al.: PEG-Interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  4. Fried MW, Shiffman ML, Reddy R, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.

    Article  PubMed  CAS  Google Scholar 

  5. Yano M, Kumada H, Hage M, et al.: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996, 23:1334–1340.

    Article  PubMed  CAS  Google Scholar 

  6. Heathcote EJ, Shiffman ML, Cooksley WGE, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673–1680.

    Article  PubMed  CAS  Google Scholar 

  7. Imazeki F, Yokosuka O, Fukai K, Saisho H: Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003, 38:493–502.

    Article  PubMed  CAS  Google Scholar 

  8. Cammà C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593–602.

    Article  PubMed  Google Scholar 

  9. Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.

    PubMed  CAS  Google Scholar 

  10. Gordon SC, Fang JWS, Silverman AL, et al.: The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000, 32:400–404.

    Article  PubMed  CAS  Google Scholar 

  11. Zeuzem S, Diago M, Gane E, et al.: Controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with Peginterferon alfa-2A (40KD) (Pegasys) and ribavirin (Copegus) [abstract]. Presented at the annual meeting of the American Association for the Study of Liver Disease, Boston, MA, October 24–28, 2003.

  12. Adinolfi LE, Gambardella M, Andreana A, et al.: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358–1364.

    Article  PubMed  CAS  Google Scholar 

  13. Hickman I, Clouston A, Macdonald G, et al.: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002, 51:89–94.

    Article  PubMed  CAS  Google Scholar 

  14. Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38:639–644.

    Article  PubMed  CAS  Google Scholar 

  15. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349:825–832.

    Article  PubMed  CAS  Google Scholar 

  16. Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis c virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562–569.

    Article  PubMed  CAS  Google Scholar 

  17. Qurishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362:1708–1713.

    Article  PubMed  CAS  Google Scholar 

  18. Soriano V, Garcia-Samaniego J, Bravo R, et al.: Interferon for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:585–591.

    PubMed  CAS  Google Scholar 

  19. Perez-Olmeda M, Nunez M, Romero M, et al.: Pegylated IFNalpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003, 17:1023–1028.

    Article  PubMed  CAS  Google Scholar 

  20. Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280–281.

    Article  PubMed  CAS  Google Scholar 

  21. Walmsley S, Heathcote J: Management and guidelines for the HCV and HIV co-infected adult: recommendations of a multidisciplinary expert panel. Can J Infect Dis 2001, 12:67–71.

    Google Scholar 

  22. Dieterich DT, Wasserman R, Brau N, et al.: Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003, 98:2491–2499.

    PubMed  CAS  Google Scholar 

  23. Pereira BJG, Natov SN, Bouthot BA, et al., and the New England Organ Bank Hepatitis C Study Group: Effect of hepatitis C infection and renal transplantation on survival in end-stage renal disease. Kidney Int 1998, 53:1374–1381.

    Article  PubMed  CAS  Google Scholar 

  24. Fabrizi F, Poordad FF, Martin P: Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002, 36:3–10.

    Article  PubMed  Google Scholar 

  25. Cacoub P, Lidove O, Maisonobe T, et al.: Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002, 46:3317–3326.

    Article  PubMed  CAS  Google Scholar 

  26. Joshi S, Heathcote EJ: The morbidity of symptomatic cryoglobulinemia and hepatitis C and response to treatment [abstract]. Gastroenterology 2003, 124(Suppl 1):57.

    Google Scholar 

  27. Medhekar S, Nutt A, Raufman JP, Jasin HE: Effect of interferon alfa-2b and ribavirin treatment on hepatitis C-associated cryoglobulinemia and rheumatoid factor: comment on the article by Vassilopoulos and Calabrese. Arthritis Rheum 2003, 48:580–581.

    Article  PubMed  Google Scholar 

  28. Silvestri F, Pipan C, Barillari G, et al.: Prevalence of hepatitis C virus infections in patients with lymphoproliferative disorders. Blood 1996, 87:4296–4301.

    PubMed  CAS  Google Scholar 

  29. Hermine O, Lefrère F, Bronowicki J-P, et al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 347:89–94.

    Article  PubMed  CAS  Google Scholar 

  30. Davis GL, Wong JB, McHutchison JG, et al.: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38:645–652.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Toronto Western Hospital, University Health Network/University of Toronto, 399 Bathurst Street, Fell Pavilion, 6th floor, Room 170, M5T 2S8, Toronto, ON, Canada

    Jenny Heathcote MD, FRCP, FRCP(C) & Alnoor Ramji MD, FRCP(C)

Authors
  1. Jenny Heathcote MD, FRCP, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alnoor Ramji MD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heathcote, J., Ramji, A. When to treat patients with chronic hepatitis C. Curr Gastroenterol Rep 6, 261–263 (2004). https://doi.org/10.1007/s11894-004-0074-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-004-0074-6

Keywords

Search

Navigation